brolucizumab

Details

Key Milestones2

Call for patient input posted August 28, 2019
Patient group input closed October 18, 2019
Clarification:

- Patient input submission received from Canadian Council of the Blind, CNIB Foundation, Fighting Blindness Canada, Vision Loss Rehabilitation Canada (Joint Submission)

Patient input summary sent for review to patient input groups December 04, 2019
Patient group comments on input summary closed December 11, 2019
Clarification:

- No patient input summary feedback received

Submission received September 26, 2019
Submission accepted November 28, 2019
Clarification:

- Submission was not accepted for review on 10-Oct-2019

- Revised category 1 requirements received on 25-Nov-2019

Review initiated November 29, 2019
Draft Canada's Drug Agency review report(s) sent to sponsor February 20, 2020
Comments from sponsor on draft Canada's Drug Agency review report(s) received March 02, 2020
Canada's Drug Agency review team's comments on draft Canada's Drug Agency review report(s) sent to sponsor April 02, 2020
Canadian Drug Expert Committee (CDEC) meeting April 15, 2020
CDEC recommendation sent to sponsor and drug plans April 29, 2020
Embargo period ended May 13, 2020
CDEC Final Recommendation & Canada's Drug Agency review report(s) issued to sponsor and drug plans May 21, 2020
CDEC Final Recommendation posted May 25, 2020
Redaction requests from sponsor on draft Canada's Drug Agency review report(s) received June 04, 2020
Clarification:

- No redactions requested by the sponsor

Final Canada's Drug Agency review report(s) posted July 03, 2020

Bisphosphonate Drugs for the Treatment of Osteoporosis in Post-Menopausal Women

Details

Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future fractures.

Dementia Villages

Details

As the population ages, decision-makers are faced with different choices of care models for people diagnosed with dementia. Recent media reports have focused on dementia villages, first developed at de Hogeweyk in the Netherlands. This Horizon Scanning bulletin will present a narrative review of the literature describing elements of care, as well as evidence and issues concerning dementia villages and similar models or components of care. Stakeholder perspectives and an analysis of policy issues will also be incorporated.